Deep Vein Thrombosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Deep Vein Thrombosis stocks.

Deep Vein Thrombosis Stocks Recent News

Date Stock Title
May 3 SNY Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
May 3 AMPH Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
May 3 NARI Inari Medical, Inc. (NASDAQ:NARI) Just Reported, And Analysts Assigned A US$66.00 Price Target
May 3 SNY Q1 2024 Kymera Therapeutics Inc Earnings Call
May 2 NARI Inari Medical, Inc. (NASDAQ:NARI) Q1 2024 Earnings Call Transcript
May 2 AMPH Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
May 2 SNY Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
May 2 SNY 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 2 NARI Inari Medical First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 2 SNY Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
May 1 SNY Sanofi Q1: Wait And See For Now (Downgrade)
May 1 NARI Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises
May 1 AMPH Amphastar Pharmaceuticals (AMPH) Reports Next Week: Wall Street Expects Earnings Growth
May 1 NARI Q1 2024 Inari Medical Inc Earnings Call
May 1 NARI Inari Medical, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 1 NARI Inari Medical, Inc. (NARI) Q1 2024 Earnings Call Transcript
May 1 NARI Inari Medical Inc (NARI) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
Apr 30 NARI Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
Apr 30 NARI Inari Medical Inc (NARI) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Rising Operating ...
Apr 30 NARI Inari Medical GAAP EPS of -$0.42 misses by $0.23, revenue of $143.19M beats by $5.43M
Deep Vein Thrombosis

Deep vein thrombosis (DVT), is the formation of a blood clot in a deep vein, most commonly the legs. Symptoms may include pain, swelling, redness, or warmth of the affected area. About half of cases have no symptoms. Complications may include pulmonary embolism, as a result of detachment of a clot which travels to the lungs, and post-thrombotic syndrome.Risk factors include recent surgery, cancer, trauma, lack of movement, obesity, smoking, hormonal birth control, pregnancy and the period following birth, antiphospholipid syndrome, and certain genetic conditions. Genetic factors include deficiencies of antithrombin, protein C, and protein S, and factor V Leiden mutation. The underlying mechanism typically involves some combination of decreased blood flow rate, increased tendency to clot, and injury to the blood vessel wall.Individuals suspected of having DVT may be assessed using a clinical prediction rule such as the Wells score. A D-dimer test may also be used to assist with excluding the diagnosis or to signal a need for further testing. Diagnosis is most commonly confirmed by ultrasound of the suspected veins. Together, DVT and pulmonary embolism are known as venous thromboembolism (VTE).Anticoagulation (blood thinners) is the standard treatment. Typical medications include low-molecular-weight heparin, warfarin, or a direct oral anticoagulant. Wearing graduated compression stockings may reduce the risk of post-thrombotic syndrome. Prevention may include early and frequent walking, calf exercises, aspirin, anticoagulants, graduated compression stockings, or intermittent pneumatic compression. The rate of DVTs increases from childhood to old age; in adulthood, about one in 1000 adults are affected per year. About 5% of people are affected by a VTE at some point in time.

Browse All Tags